Entera Bio Ltd is committed to developing innovative therapies for various gastrointestinal diseases. With a focus on oral drug delivery, the company aims to improve patients' quality of life by providing convenient treatment options. Entera Bio values scientific excellence and strives to deliver effective solutions through its proprietary technology platform. The company's corporate philosophy centers around patient-centricity, continuous research and development, and fostering collaborations with key industry partners. With a strong commitment to clinical advancement and a steadfast dedication to enhancing therapeutic outcomes, Entera Bio Ltd aims to make a positive impact in the field of gastrointestinal healthcare.

Entera Bio Ltd is primarily present in the United States and Israel.

Entera Bio Ltd has achieved several significant milestones. The company successfully completed a Phase 2 clinical trial for its lead product, EB613, a novel oral parathyroid hormone (PTH) tablet for the treatment of osteoporosis and hypoparathyroidism. Entera Bio also obtained positive results from a pharmacokinetic study for EB612, an oral recombinant human parathyroid hormone (rhPTH(1-34)) for the treatment of hypoparathyroidism. Furthermore, the company recently announced a strategic collaboration with Amgen to develop and commercialize oral PTH treatments. These milestones highlight Entera Bio's progress in developing innovative oral drug delivery solutions, positioning the company as a leader in the field of oral PTH therapies.

Entera Bio Ltd. is a biotechnology company that specializes in the development and commercialization of oral peptide drugs. Founded in 2010, Entera Bio is headquartered in Jerusalem, Israel. The company's proprietary oral delivery technology, known as the Peptide Absorption Technology (PAT), enables the oral administration of peptides, which are usually administered through injections. This innovative approach has the potential to revolutionize the treatment of various diseases and conditions. Entera Bio has a robust pipeline of oral drug candidates targeting different therapeutic areas, including osteoporosis, hypoparathyroidism, and non-alcoholic steatohepatitis (NASH). With its cutting-edge technology and strong focus on research and development, Entera Bio aims to improve patient outcomes and provide innovative solutions in the field of oral peptide therapeutics.

Some of the main competitors of Entera Bio Ltd in the market include Amgen Inc., Eli Lilly and Company, and Novartis AG. These companies are also involved in the development and commercialization of innovative biopharmaceutical products.

Entera Bio Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of Entera Bio Ltd. focuses on developing and commercializing oral drug formulations based on its proprietary oral protein delivery technology. Entera Bio aims to address the limitations of injectable drugs by offering a convenient and patient-friendly alternative through their oral drug delivery platform. By leveraging their technology, Entera Bio is able to develop and deliver various therapies, including parathyroid hormone (PTH) for the treatment of osteoporosis and other bone diseases. This innovative approach has the potential to revolutionize the treatment landscape, providing a more accessible and effective solution for patients.

P/E-lukua ei voida tällä hetkellä laskea kohteelle Entera Bio.

KUV:tä ei voida tällä hetkellä laskea Entera Bio osalta.

AlleAktien Laatuscore Entera Bio on 1/10.

Liikevaihtoa ei voida tällä hetkellä laskea yritykselle Entera Bio.

odotettu Entera Bio voitto on −20,66 milj. USD.

Enter Bio Ltd is a biopharmaceutical company specializing in the development and marketing of innovative oral peptide therapies. The company's business model is based on the goal of increasing the therapeutic possibilities of peptides through the development of an oral formulation. This utilizes the benefits of peptide therapy, such as high effectiveness and low toxicity, while bypassing the difficulty of using peptides as injectable drugs. Enter Bio has three different business areas: drug development, active substance manufacturing, and licensing and partnerships. In drug development, innovative peptide-based medications for diseases in the areas of osteoporosis, diabetes, and HIV are being developed. Enter Bio works closely with many academic institutions and industry partners to utilize and further develop innovative technologies for peptide development and oral medication manufacturing. Another important business area of Enter Bio is active substance manufacturing. The company has a patented technology for peptide manufacturing and oralization, which allows for the production of peptides with high purity and effectiveness. This enables the company to meet the demand for drug active substances in the field of peptide therapy. Enter Bio also offers licensing and partnerships for partners who want to develop and market their own patents and take advantage of Enter Bio's patented technologies. Enter Bio operates an open and flexible licensing policy to ensure a wider use of oral peptide therapeutics. An important product of Enter Bio is the peptide therapy EB613 for osteoporosis. It is an oralization platform that allows the oral administration of the peptide PTH 1-34, a known anabolic agent for the treatment of osteoporosis. This medication can be an alternative to the currently available injectable medications, which is particularly beneficial for patients. Another important product of Enter Bio is EB612 for diabetes. This is an oral GLP-1 peptide agonist developed as an alternative to injectable peptide agonists for the treatment of diabetes. Unlike other orally absorbable peptides, EB612 has higher stability and a longer half-life, improving the effectiveness and compliance of the therapy. In summary, Enter Bio Ltd is an advanced biopharmaceutical company specializing in the development of oral peptide therapies. The company has built a unique technology platform that allows for the successful formulation, production, and marketing of peptides in oral medications. By offering innovative peptide therapeutics for osteoporosis, diabetes, and HIV, as well as services for active substance manufacturing and licensing and partnerships, Enter Bio contributes to creating new possibilities for the treatment of serious diseases and improving the quality of life for patients.

Entera Bio maksaa osinkoa 0 USD, joka jaetaan erässä vuoden aikana.

Osinkoa ei voida tällä hetkellä laskea Entera Bio:lle tai yhtiö ei maksa osinkoa.

Entera Bio:n ISIN on IL0011429839.

Entera Bio:n WKN on A2JQXP.

Entera Bio:n tunnus on ENTX.

Viimeisen 12 kuukauden aikana Entera Bio maksoi osinkoa edestä. Tämä vastaa noin osinkotuottoa. Seuraavan 12 kuukauden aikana Entera Bio maksanee ennusteiden mukaan 0 USD osingon.

Entera Bio:n tämänhetkinen osinkotuotto on .

Entera Bio maksaa osinkoa neljännesvuosittain. Osingot jaetaan kuukausina .

Entera Bio maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Seuraavalle 12 kuukaudelle odotetaan 0 USD suuruisia osinkoja. Tämä vastaa 0 % osinkotuottoa.

Entera Bio kuuluu sektoriin 'Terveys'.

Saadaksesi viimeisimmän Entera Bio osingon 29.1.2025, jonka suuruus on 0 USD, sinun oli oltava omistanut osakkeen ennen ex-päivää, joka oli 29.1.2025.

Viimeisin osinko maksettiin 29.1.2025.

Vuonna 2024 Entera Bio maksoi 0 USD osinkoina.

Entera Bio:n osingot maksetaan USDssa.